Cérivastatine
En pharmacologie, la cérivastatine (Baycol, Lipobay, Cholstat, Staltor) était un médicament synthétique de la classe des statines, qui était utilisé pour diminuer la cholestérolémie et prévenir les maladies cardiovasculaires. Il a été retiré du marché en 2001 à cause du taux élevé d'effets secondaires graves.
Texte anglais à traduire :
Cerivastatin was marketed by the pharmaceutical company Bayer A.G. in the late 1990s as a new synthetic statin, to compete with Pfizer's highly successful atorvastatin.
During post-marketing surveillance, 52 deaths were reported in patients using cerivastatin, mainly from rhabdomyolysis and its resultant renal failure. Risks were higher in patients using fibrates (mainly gemfibrozil) and in patients using the high (0.8 mg/day) dose of cerivastatin. Another 385 nonfatal cases of rhabdomyolysis were reported. This put the risk of this (rare) complication at 5-10 times that of the other statins.
In 2001, Bayer announced the voluntary withdrawal of the drug from the market.
| Cérivastatine | |
| |
| Identification | |
|---|---|
| No CAS | |
| Code ATC | C10 |
| SMILES | |
| InChI | |
| Propriétés chimiques | |
| Formule | C26H34FNO5 [Isomères] |
| Masse molaire[1] | 459,5503 ± 0,0249 g/mol C 67,95 %, H 7,46 %, F 4,13 %, N 3,05 %, O 17,41 %, |
| Unités du SI et CNTP, sauf indication contraire. | |
Références
- (en) Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-207. .
- (en) World Health Organization - Alert: Voluntary withdrawal of Cerivastatin – Reports of Rhabdomyolysis.
- Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.
Portail de la pharmacie 
Portail de la chimie